Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing novel therapeutics for muscular dystrophies and serious cardiac conditions. It has built its muscle-focused drug discovery platform. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. Its lead product candidate, EDG-5506, is an orally administered allosteric, selective, fast myofiber (type II) myosin small molecule inhibitor designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. Its product candidate, EDG-7500, for the treatment of hypertrophic cardiomyopathy addition to exploring the potential of its mechanism in the treatment of disorders of diastolic dysfunction.